Advertisement

Advertisement

Lymphoma
Immunotherapy

Changing the Algorithm for Relapsed or Refractory Large B-Cell Lymphomas

Despite a significant potential for cure, relapsed and refractory large B-cell lymphomas (LBCL) comprise the most common cause of lymphoma-related mortality. Sequential relapses reflect the limits of repeated exposure to chemotherapy, even when delivered at high doses. More than 30 years ago,...

Lymphoma

Determining Prognosis in Aggressive Lymphomas: Integrating Liquid Biopsy Into Imaging Assessment

The incorporation of blood-based measurements—ie, “liquid biopsies”—into imaging assessment may refine the accuracy of prognosis in aggressive lymphomas, as described by David Kurtz, MD, PhD, Assistant Professor in the Division of Oncology, Stanford University Medical Center, in a talk at the 2022...

Lymphoma

Axicabtagene Ciloleucel Improves Event-Free Survival vs Standard Care in Second-Line Treatment for Large B-Cell Lymphoma

As reported in The New England Journal of Medicine by Frederick L. Locke, MD, of the Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center, Tampa, Florida, and colleagues, the phase III ZUMA-7 trial in large B-cell lymphoma has shown improved event-free...

Skin Cancer
Lymphoma

Trends in Incidence of Cutaneous T-Cell Lymphoma in the United States

In a study reported in a research letter in JAMA Oncology, Cai et al found that the incidence of cutaneous T-cell lymphoma increased in the United States between 2000 and 2018. The study involved data from 18 Surveillance, Epidemiology, and End Results (SEER) Program registries for 2000 to 2018. A...

Lymphoma

An Aggressive Type of Non-Hodgkin Lymphoma Threatened My Life

I was just 31 and about to give birth to my fourth child, Yitzchok, when I received a diagnosis of primary mediastinal large B-cell lymphoma. The news was terrifying and crippling. For months, I had been experiencing shortness of breath, coughing, and a pain in my left shoulder, all of which were...

Leukemia
Lymphoma
Myelodysplastic Syndromes

FDA Approves Pemigatinib for Patients With Myeloid/Lymphoid Neoplasms and FGFR1 Rearrangement

On August 26, the U.S. Food and Drug Administration (FDA) approved pemigatinib (Pemazyre), a selective fibroblast growth factor receptor (FGFR) inhibitor, for the treatment of adults with relapsed or refractory myeloid/lymphoid neoplasms with FGFR1 rearrangement. Myeloid/lymphoid neoplasms with...

Lymphoma

Tisagenlecleucel for Relapsed or Refractory Follicular Lymphoma

On May 27, 2022, tisagenlecleucel, a CD19 chimeric antigen receptor (CAR) T-cell therapy, was granted accelerated approval for adults with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy.1 Supporting Efficacy Data Approval was based on the multicenter ELARA...

lymphoma

Anna Sureda, MD, PhD, on Large B-Cell Lymphoma: New Data on Axicabtagene Ciloleucel vs Standard of Care

Anna Sureda, MD, PhD, of the University of Barcelona and the Catalan Institute of Oncology, discusses phase III clinical and patient-reported outcomes from the ZUMA-7 trial, which showed that axicabtagene ciloleucel was superior to second-line standard-of-care treatment in patients 65 years or older with relapsed or refractory large B-cell lymphoma (Abstract S211).

Lymphoma

Rituximab, Lenalidomide, and Ibrutinib With Sequential Addition of Chemotherapy in Newly Diagnosed DLBCL: Smart Start Trial

In a single-institution phase II trial (Smart Start) reported in the Journal of Clinical Oncology, Jason Westin, MD, MS, and colleagues found that initiating treatment with rituximab, lenalidomide, and ibrutinib (RLI) followed by the sequential addition of chemotherapy resulted in high response...

Lymphoma

Lisocabtagene Maraleucel in Second-Line Treatment of Large B-Cell Lymphoma

On June 24, 2022, lisocabtagene maraleucel was approved for adults with large B-cell lymphoma (LBCL) who have (1) refractory disease to first-line chemoimmunotherapy or relapse within 12 months of first-line chemoimmunotherapy; or (2) refractory disease to first-line chemoimmunotherapy or relapse...

Lymphoma
Immunotherapy

Expert Point of View: Alexey V. Danilov, MD, PhD

According to Alexey V. Danilov, MD, PhD, Professor and Co-Director, Toni Stephenson Lymphoma Center, City of Hope, diffuse large B-cell lymphoma (DLBCL) refractory to chemotherapy represents an unmet medical need, with data from the SCHOLAR-1 study demonstrating a median overall survival of...

Lymphoma
Immunotherapy

Epcoritamab Under Study in Difficult-to-Treat Large B-Cell Lymphoma

Subcutaneous epcoritamab, a bispecific antibody, has demonstrated deep and durable responses in a large expansion cohort of patients with relapsed or refractory large B-cell lymphoma (LBCL), according to late-breaking data presented during the European Hematology Association (EHA) 2022 Congress in...

Lymphoma

Risk Prediction Models for Coronary Heart Disease and Heart Failure After Treatment for Hodgkin Lymphoma

In a study reported in the Journal of Clinical Oncology, de Vries et al developed risk models for predicting the development of coronary heart disease and heart failure in patients treated for Hodgkin lymphoma. Study Details The prediction models were developed in a Dutch cohort of 1,433 5-year...

Lymphoma

First-Line Lenalidomide/Rituximab vs Rituximab/Chemotherapy With Rituximab Maintenance for Advanced Follicular Lymphoma

As reported in the Journal of Clinical Oncology by Franck Morschhauser, MD, PhD, and colleagues, 6-year results from the second interim analysis of the phase III RELEVANCE trial show similar progression-free and overall survival with lenalidomide/rituximab (R2) vs rituximab/chemotherapy (R-chemo)...

Lymphoma
Genomics/Genetics

Study Reveals Potential Genomic Contributors to the Development of DLBCL

By searching previously ignored regions of the genome, researchers have found a multitude of new genetic mutations that may contribute to diffuse large B-cell lymphoma (DLBCL). These findings were published by Bal et al in Nature. “Our findings not only show that these mutations can contribute to...

Lymphoma

Brentuximab Vedotin Plus AVD vs ABVD for the First-Line Treatment of Early-Stage Unfavorable-Risk Hodgkin Lymphoma

In a European phase II trial (BREACH) reported in the Journal of Clinical Oncology, Fornecker et al found that brentuximab vedotin (BV) plus doxorubicin, vinblastine, and dacarbazine (BV-AVD) improved the rate of positron-emission tomography (PET)-negative status after two cycles of treatment vs...

Lymphoma

Consolidation Radiotherapy vs Autologous Stem Cell Transplantation for Primary CNS Lymphoma

As reported in the Journal of Clinical Oncology by Houillier et al, 8-year follow-up in the French phase II PRECIS trial has shown a maintained event-free survival benefit with autologous stem cell transplantation (ASCT) vs whole-brain radiotherapy (WBRT) as consolidation in patients aged ≤ 60...

Leukemia
Lymphoma

Zandelisib in Continuous or Intermittent Dosing Schedules With or Without Rituximab for Relapsed or Refractory B-Cell Malignancies

In a first-in-patients phase Ib study reported in The Lancet Oncology, John M. Pagel, MD, PhD, and colleagues identified the safety profiles of the PI3Kδ inhibitor zandelisib given in intermittent vs continuous dosing schedules with or without rituximab in patients with relapsed of refractory...

Lymphoma

ECHELON-1 Trial: Brentuximab Vedotin With Chemotherapy Offers Survival Benefit in Stage III or IV Hodgkin Lymphoma

Brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine (a regimen known as A+AVD) significantly reduced the risk of mortality vs standard treatment with doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) in patients with previously untreated stage III or IV classical Hodgkin...

Leukemia
Lymphoma

Zanubrutinib vs Bendamustine/Rituximab in Previously Untreated Patients With CLL or SLL

As reported in The Lancet Oncology by Constantine S. Tam, MBBS, PhD, and colleagues, an interim analysis in the phase III SEQUOIA trial has shown significantly improved progression-free survival with first-line zanubrutinib vs bendamustine/rituximab in patients with chronic lymphocytic leukemia...

Lymphoma
Immunotherapy

Second-Line Lisocabtagene Maraleucel in Patients With Relapsed or Refractory Large B-Cell Lymphoma Not Intended for HSCT

As reported in The Lancet Oncology by Sehgal et al, the phase II PILOT trial showed that the autologous, CD19-directed chimeric antigen receptor (CAR) T-cell product lisocabtagene maraleucel produced a high response rate in the second-line treatment of patients with relapsed or refractory large...

Lymphoma
Immunotherapy

Addition of Brentuximab Vedotin to Chemotherapy in Patients With Stage III or IV Hodgkin Lymphoma: Overall Survival Analysis From ECHELON-1

As reported in The New England Journal of Medicine by Stephen M. Ansell, MD, PhD, and colleagues, an analysis at 6 years of follow-up in the phase III ECHELON-1 trial has shown significantly improved overall survival with brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine (A+AVD) vs ...

Lymphoma

Do Bone Marrow Biopsies Aid in Response Assessment for Patients With Follicular Lymphoma?

In a pooled analysis of patients with follicular lymphoma treated in National Clinical Trials Network trials reported in the Journal of Clinical Oncology, Rutherford et al found evidence that bone marrow biopsies can be avoided in response assessment. The investigators stated, “Bone marrow biopsies ...

lymphoma
immunotherapy

Michael Dickinson, MBBS, on DLBCL: Phase II Expansion Results on Glofitamab

Michael Dickinson, MBBS, of the Peter MacCallum Cancer Centre, the Royal Melbourne Hospital, and The University of Melbourne, discusses new data, which showed that fixed-duration glofitamab induces durable complete remissions with a favorable safety profile in patients with or refractory diffuse large B-cell lymphoma and two or more prior therapies, including exposure to CAR T cells (Abstract 7500).

Lymphoma
Immunotherapy

Bispecific Antibody Mosunetuzumab in Relapsed or Refractory Follicular Lymphoma

In a phase II study reported in The Lancet Oncology, L. Elizabeth Budde, MD, PhD, and colleagues found that mosunetuzumab—a CD20 × CD3 T-cell–engaging bispecific antibody that redirects T cells to eliminate malignant B cells—produced a high rate of complete response in patients with relapsed or...

Lymphoma

Real-World Treatment Outcomes With Transplantation and Maintenance Rituximab in Previously Untreated Patients With Mantle Cell Lymphoma

In a U.S. “real-world” retrospective cohort study of patients receiving first-line treatment for mantle cell lymphoma reported in the Journal of Clinical Oncology, Peter Martin, MD, and colleagues found that autologous stem cell transplantation (ASCT) did not significantly improve the time to next...

Lymphoma
Immunotherapy

Lisocabtagene Maraleucel as Second-Line Treatment for Relapsed or Refractory Large B-Cell Lymphoma: TRANSFORM Trial

As reported in The Lancet by Manali Kamdar, MD, and colleagues, an interim analysis of the phase III TRANSFORM trial has shown significantly improved event-free survival with second-line lisocabtagene maraleucel vs standard-of-care salvage immunochemotherapy followed by autologous hematopoietic...

Leukemia
Lymphoma

FDA Warns About Possible Increased Risk of Death and Serious Side Effects With Duvelisib

The U.S. Food and Drug Administration (FDA) is warning that results from the phase III DUO clinical trial show a possible increased risk of death with duvelisib compared to ofatumumab among patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The trial also found...

Lymphoma

Direct-Acting Antivirals in HCV-Associated Indolent Non-Hodgkin Lymphomas

As reported in the Journal of Clinical Oncology by Merli et al, the Fondazione Italiana Linfomi phase II BArT study has shown that primary treatment of hepatitis C virus (HCV)-associated indolent non-Hodgkin lymphomas with direct-acting antivirals resulted in sustained virologic response in all...

Lymphoma
Immunotherapy

FDA Approves Lisocabtagene Maraleucel for the Second-Line Treatment of Large B-Cell Lymphoma

On June 24, the U.S. Food and Drug Administration (FDA) approved the chimeric antigen receptor (CAR) T-cell therapy lisocabtagene maraleucel (Breyanzi) for adult patients with large B-cell lymphoma (LBCL) who have disease refractory to first-line chemoimmunotherapy or relapse within 12 months of...

lymphoma

Relapsed/Refractory Hodgkin Lymphoma

This is Part 4 of Updates in Lymphoma, a four-part video roundtable series. Scroll down to watch the other videos from this Roundtable. In this video, Drs. Alison J. Moskowitz, Andrew M. Evens, and Ann S. LaCasce discuss the management of relapsed/refractory Hodgkin lymphoma. The patient is a 36-year-old woman who was originally diagnosed with stage IIIB classical Hodgkin lymphoma with a 12-cm mediastinal mass and an IPS of 2. She received BV-AVD for 6 cycles, with a PET-negative response after two and six cycles of treatment. However, repeat PET scan showed new and increasing hypermetabolic masses in the anterior mediastinum. The faculty discuss treatment options for patients with primary refractory disease, including brentuximab vedotin plus nivolumab and pembrolizumab plus gemcitabine, vinorelbine, and doxorubicin.

lymphoma

Hodgkin Lymphoma in Patients Age ≥ 60 Years

This is Part 3 of Updates in Lymphoma, a four-part video roundtable series. Scroll down to watch the other videos from this Roundtable. In this video, Drs. Alison J. Moskowitz, Andrew M. Evens, and Ann S. LaCasce discuss Hodgkin lymphoma in patients age ≥ 60 years. The patient is a 65-year-old man who is diagnosed with stage IV Hodgkin lymphoma, IPS of 4, with FDG uptake in lymph nodes and the bones. The faculty discuss the treatment options older patients, the importance of geriatric assessment, and when front-line palliative therapy with brentuximab vedotin may be appropriate.  

lymphoma

Bulky Early-Stage Hodgkin Lymphoma

This is Part 2 of Updates in Lymphoma, a four-part video roundtable series. Scroll down to watch the other videos from this Roundtable. In this video, Drs. Alison J. Moskowitz, Andrew M. Evens, and Ann S. LaCasce discuss the management of bulky early-stage Hodgkin lymphoma. The patient is a 23-year-old woman who is diagnosed with classical Hodgkin lymphoma and bilateral cervical and mediastinal lymphadenopathy (measuring > 13 cm) with pleural effusion. The faculty discuss the results of the Alliance 50801 study of PET-adapted therapy in bulky Hodgkin lymphoma and situations where radiotherapy can be omitted in patients with bulky disease.

lymphoma

Advanced-Stage Hodgkin Lymphoma

This is Part 1 of Updates in Lymphoma, a four-part video roundtable series. Scroll down to watch the other videos from this Roundtable. In this video, Drs. Alison J. Moskowitz, Andrew M. Evens, and Ann S. LaCasce discuss the management of advanced-stage Hodgkin lymphoma. The patient is a 35-year-old woman who presents with cough and is diagnosed with stage IV Hodgkin lymphoma with metastases in her lung and liver and IPS of 3. The faculty discuss the implications of the ECHELON-1 trial of brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine vs doxorubicin, bleomycin, vinblastine, and dacarbazine, as well as the role of PET-directed therapy in the treatment of these patients. Editor’s Note: This video was filmed prior to the presentation of the ECHELON-1 data at the 2022 ASCO Annual Meeting.  

lymphoma

Andrew D. Zelenetz, MD, PhD, and Michael L. Wang, MD, on Mantle Cell Lymphoma: New Data on Ibrutinib in Combination With Bendamustine/Rituximab and Rituximab Maintenance

Andrew D. Zelenetz, MD, PhD, of Memorial Sloan Kettering Cancer Center, and Michael L. Wang, MD, of The University of Texas MD Anderson Cancer Center, discuss primary results from the phase III SHINE study, which showed that ibrutinib, in combination with bendamustine/rituximab and rituximab maintenance, may set a new benchmark for patients aged 65 or older with mantle cell lymphoma. With a median progression-free survival of 6.7 years, the ibrutinib combination is more beneficial than currently used chemoimmunotherapy (approximately 1.5–3.5 years) (Abstract LBA7502).

Lymphoma
Immunotherapy

Allogeneic CAR T-Cell Therapy for Relapsed or Refractory T-Cell Lymphoma

Patients with relapsed or refractory T-cell lymphoma have limited treatment options. Chimeric antigen receptor (CAR) T-cell therapy has been challenging in these patients because of the state of their T cells. CTX130 is an allogeneic CAR T-cell therapy targeting CD70 on cancerous T cells, offering...

Lymphoma
Immunotherapy

Brexucabtagene Autoleucel in Relapsed or Refractory Mantle Cell Lymphoma: 3-Year Follow-up of ZUMA-2 Trial

In an analysis presented at the 2022 ASCO Annual Meeting (Abstract 7518) and simultaneously reported in the Journal of Clinical Oncology, Michael Wang, MD, and colleagues provided data from the 3-year follow-up of the pivotal ZUMA-2 trial of the chimeric antigen receptor (CAR) T-cell therapy...

lymphoma
immunotherapy

Stephen M. Ansell, PhD, MD, on Hodgkin Lymphoma: An Updated Analysis on First-Line Brentuximab Vedotin Plus Chemotherapy

Stephen M. Ansell, PhD, MD, of Mayo Clinic, discusses updated data from the ECHELON-1 trial, which showed that, when administered to patients with stage III or IV classical Hodgkin lymphoma, the combination of brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine (A+AVD) vs doxorubicin, bleomycin, vinblastine, and dacarbazine resulted in a 41% reduction in the risk of death. These outcomes, says Dr. Ansell, confirm A+AVD as a preferred option for previously untreated disease (Abstract 7503).

Lymphoma

Ibrutinib Added to Standard Therapy Prolongs Progression-Free Survival in Older Patients With Mantle Cell Lymphoma

Primary results from the phase III SHINE trial demonstrated that first-line treatment with ibrutinib combined with bendamustine/rituximab and rituximab maintenance achieves a substantial prolongation of progression-free survival in elderly patients with mantle cell lymphoma, according to a...

Lymphoma
Immunotherapy

FDA Approves Tisagenlecleucel for Adult Patients With Relapsed or Refractory Follicular Lymphoma

On May 28, the U.S. Food and Drug Administration (FDA) granted accelerated approval to the chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel (Kymriah) for the treatment of adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy....

Lymphoma

Finding a New Normal After Classical Hodgkin Lymphoma

As every patient diagnosed with cancer knows, the disease affects not just your physical well-being, but your emotional well-being, too. I was just 35 years old when I was diagnosed with early-stage classical Hodgkin lymphoma this past summer, and the news came at a time when I was feeling in top...

Lymphoma

Axicabtagene Ciloleucel for Second-Line Treatment of Large B-Cell Lymphoma

On April 1, 2022, axicabtagene ciloleucel was approved for adults with large B-cell lymphoma that is refractory to first-line chemoimmunotherapy or relapses within 12 months of first-line chemoimmunotherapy.1 It is not indicated for the treatment of patients with primary central nervous system...

Gastrointestinal Cancer
Breast Cancer
Survivorship
Multiple Myeloma
Lymphoma

NCCN Clinical Practice Guidelines in Oncology: 2022 Updates

In 1996, the National Comprehensive Cancer Network® (NCCN®) published its first set of Clinical Practice Guidelines in Oncology® covering eight tumor types. Guidelines are now published for more than 60 tumor types, subtypes, and topics. During the NCCN’s 27th Annual Conference, which was again...

Lymphoma
Immunotherapy

Report Investigates Potential Causes of Decreasing Responses to CAR T-Cell Therapy in Patients With Non-Hodgkin Lymphoma

A study published by Jackson et al in Cancer Discovery investigated the reasons for decreased remission rates for patients with non-Hodgkin lymphoma treated with chimeric antigen receptor (CAR) T-cell therapy. "CAR T-cell therapy is a promising treatment for non-Hodgkin lymphoma, especially for...

Hematologic Malignancies
Multiple Myeloma
Lymphoma
Leukemia

Prevalence of Plasma Cell and Lymphoproliferative Disorders in Relatives of Probands With Light Chain Amyloidosis

In a study reported in the British Journal of Haematology, Staron et al found that the prevalence of plasma cell and lymphoproliferative disorders among blood relatives of probands with light chain (AL) amyloidosis was low overall and varied according to proband AL amyloidosis subtype. Despite...

Immunotherapy
Hematologic Malignancies
Leukemia
Lymphoma

Rehospitalization and Emergency Department Visits After CAR T-Cell Therapy in Commercially Insured Patients With Cancer

In a single-institution study reported in a research letter in JAMA Oncology, Kenzik et al found substantial rates of rehospitalization and emergency department visits after chimeric antigen receptor (CAR) T-cell therapy among commercially insured patients with cancer. Study Details The study...

Lymphoma

The WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues

The ASCO Post is pleased to present Hematology Expert Review, an ongoing feature that quizzes readers on issues in hematology. In this installment, Drs. Syed Ali Abutalib and L. Jeffrey Medeiros explore the updated World Health Organization (WHO) classification of hematopoietic and lymphoid tissue...

Lymphoma
Immunotherapy

Natural Killer Cells Precomplexed With Innate Cell Engager Show Activity in CD30-Positive Lymphoma

Natural killer (NK) cells derived from donated umbilical cord blood, activated with a novel bispecific antibody targeting CD16A and CD30 known as AFM13, have yielded responses in patients with pretreated and refractory CD30-positive lymphoma. The overall response rate was 89%, with 53% complete...

Hematologic Malignancies
Leukemia
Lymphoma
Multiple Myeloma
Immunotherapy

Hematologic Oncology 2021–2022 Almanac

Ongoing evaluation of novel, targeted, and immunotherapies has led to exciting advances across the array of hematologic malignancies over the past year. The availability of new treatment options, along with emerging data on novel combinations and sequencing approaches, is rapidly changing...

Lymphoma
Immunotherapy

BELINDA Trial: CAR T-Cell Therapy Fails to Improve Outcomes in Aggressive Non-Hodgkin Lymphoma

The autologous chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel failed to improve event-free survival vs standard-of-care treatment strategies in patients with aggressive, relapsed or refractory non-Hodgkin lymphoma (NHL), according to results of the phase III BELINDA trial,...

Advertisement

Advertisement

Advertisement